12.25.14
The first surgery has been performed with Episealer knee trochlea, the second commercial product from Swedish company Episurf Medical. Episealer knee trochlea is intended to treat cartilage defects in the area behind the patella (kneecap). The surgery was carried out by orthopedic surgeon Peter Verdonk, M.D., from AZ Monica Hospital in Belgium. The patient was a 47-year-old male with knee pain despite previous inventions.
“It is known that biological treatment solutions are less effective for middle aged patients, which means that Episurf’s personalized implants can fill a need for this group of patients,” said Verdonk. “The implant fitted perfectly in the damaged area and could be placed with excellent precision. The surgery also took less time because patient specific instruments were used instead of standard instruments. This individualized approach enables me to customize the surgery to the patient’s anatomy and optimize the implant positioning.”
“Professor Verdonk is one of the most recognized orthopedic surgeons in Europe and we are delighted that he has chosen to use Episurf’s implant for a patient who previously lacked adequate treatment options,” said CEO of Episurf Nina Bake. “The patients we target are often active people of working age who only have been offered painkillers and sick leave to ease their discomfort. By using Episurf’s personalized implant, we can not only save patients long-term pain and suffering, we can also achieve substantial savings for the society in terms of reduced sick leave.”
Episealer knee trochlea received CE-certification in October and has since been offered to selected clinics in Europe via a controlled product launch CPL. The company’s first product, the personalized implant Episealer femoral condyle, has been in a CPL since fall of last year.
Episurf Medical makes patient-specific implants and surgical instruments for the treatment of painful joint injuries.
“It is known that biological treatment solutions are less effective for middle aged patients, which means that Episurf’s personalized implants can fill a need for this group of patients,” said Verdonk. “The implant fitted perfectly in the damaged area and could be placed with excellent precision. The surgery also took less time because patient specific instruments were used instead of standard instruments. This individualized approach enables me to customize the surgery to the patient’s anatomy and optimize the implant positioning.”
“Professor Verdonk is one of the most recognized orthopedic surgeons in Europe and we are delighted that he has chosen to use Episurf’s implant for a patient who previously lacked adequate treatment options,” said CEO of Episurf Nina Bake. “The patients we target are often active people of working age who only have been offered painkillers and sick leave to ease their discomfort. By using Episurf’s personalized implant, we can not only save patients long-term pain and suffering, we can also achieve substantial savings for the society in terms of reduced sick leave.”
Episealer knee trochlea received CE-certification in October and has since been offered to selected clinics in Europe via a controlled product launch CPL. The company’s first product, the personalized implant Episealer femoral condyle, has been in a CPL since fall of last year.
Episurf Medical makes patient-specific implants and surgical instruments for the treatment of painful joint injuries.